Personalisierte Therapie von Lungenkrebs

Schlüsselwörter

Bronchialkarzinom - NSCLC - Erlotinib - zielgerichtete Therapie

Keywords

bronchial carcinoma - NSCLC - erlotinib - targeted therapy

• Literatur

• 1 Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139
• 2 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957
• 3 Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500
• 4 Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73
• 5 Shields AF, Grierson JR, Dohmen BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med 1998; 4: 1334-1336
• 6 Ullrich R, Backes H, Li H et al. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 2008; 14: 2049-2055
• 7 Ullrich RT, Zander T, Neumaier B et al. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One 2008; 3: e3908
• 8 Zander T, Scheffler M, Nogova L et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 2011; 29: 1701-1708